PDCD1 and cancer: With the development of chimeric antigen receptor T cell (CAR-T) immunotherapy and immune checkpoint inhibitors (ICIs) such as anti-PD-1/PD-L1 antibodies, cancer immunotherapy has shown attractive potential in the treatment of various solid tumors (5, 6).